<SEC-DOCUMENT>0001213900-24-086415.txt : 20241009
<SEC-HEADER>0001213900-24-086415.hdr.sgml : 20241009
<ACCEPTANCE-DATETIME>20241009091325
ACCESSION NUMBER:		0001213900-24-086415
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241009
FILED AS OF DATE:		20241009
DATE AS OF CHANGE:		20241009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41084
		FILM NUMBER:		241361627

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0217150-6k_neurosense.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer Pursuant to Rule&nbsp;13a-16
or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of October 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-41084</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NeuroSense Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>11 HaMenofim Street, Building B<BR>
Herzliya 4672562 Israel<BR>
+972-9-7996183<BR>
</B>(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form&nbsp;20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2024, NeuroSense Therapeutics Ltd.
(the &ldquo;Company&rdquo;) issued a press release entitled &ldquo;NeuroSense Therapeutics Plans to File for Early Commercialization of
ALS Treatment in Canada.&rdquo; A copy of the press release is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Report on Form 6-K and the first paragraph
of the press release attached as Exhibit 99.1 are hereby incorporated by reference into the registrant&rsquo;s Registration Statements
on <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390022005072/ea154846-s8_neurosense.htm">Form S-8</A> (File No. 333-262480)
and Form F-3 (File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390023003838/ea171892-f3_neurosense.htm">333-269306</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024030451/ea0203321-posam_neurosense.htm">333-260338</A>),&nbsp;to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents
or reports subsequently filed or furnished.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea021715001ex99-1_neurosense.htm">Press Release, dated October 9, 2024, entitled &ldquo;NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada.&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroSense Therapeutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 9, 2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">3</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; text-align: center; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021715001ex99-1_neurosense.htm
<DESCRIPTION>PRESS RELEASE, DATED OCTOBER 9, 2024, ENTITLED "NEUROSENSE THERAPEUTICS PLANS TO FILE FOR EARLY COMMERCIALIZATION OF ALS TREATMENT IN CANADA."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NeuroSense Therapeutics Plans to File for&nbsp;Early Commercialization of ALS Treatment in Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results
which show PrimeC reduces ALS disease progression by 36% and improves survival rates by 43%</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><I>Company plans to seek approval in additional countries</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CAMBRIDGE, Mass.,&nbsp;Oct. 9,
2024&nbsp;/PRNewswire/ --&nbsp;NeuroSense Therapeutics Ltd.&nbsp;(NASDAQ: NRSN) (&ldquo;NeuroSense&rdquo; or the &ldquo;Company&rdquo;), a late-clinical
stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has initiated the
regulatory process to seek early commercialization approval for PrimeC under Health Canada&rsquo;s Notice of Compliance with
Conditions (NOC/c) policy. This submission is based on the promising results from the Company&rsquo;s Phase 2b ALS PARADIGM clinical
trial, alongside supporting clinical and preclinical data.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This decision aligns with the
recommendations of Canadian regulatory experts and follows recent clinical findings, where PrimeC demonstrated a <B>36% reduction in
disease progression (p=0.009) </B>and a <B>43% improvement in survival rates</B>&nbsp;compared to placebo, underscoring its
potential as a breakthrough therapy for ALS.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alon Ben-Noon, NeuroSense CEO expressed optimism about the Company&rsquo;s
prospects: &ldquo;We are excited to take this important step toward bringing PrimeC to ALS patients in Canada. The compelling results from
our clinical trials give us confidence that PrimeC can address the urgent unmet needs in ALS treatment. Our goal is to expedite access
to this promising therapy, and we are committed to advancing regulatory approvals in Canada and beyond.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ALS</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amyotrophic lateral sclerosis (&ldquo;ALS&rdquo;) is an incurable neurodegenerative
disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with
ALS in the U.S. alone, with an annual disease burden of&nbsp;$1 billion. The number of people living with ALS is expected to grow by 24%
by 2040 in the U.S. and EU.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ALSFRS-R</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disease progression is measured by the ALS Functional Rating Scale-Revised
(ALSFRS-R), which is the most widely used ALS tracking tool accepted by the FDA, utilized by neurologists treating ALS patients, in clinical
trials, and by other regulators to determine disease progression. It tracks 12 changes in a person&rsquo;s physical abilities over time including
functions such as: speech, walking, climbing stairs, dressing/hygiene, handwriting, turning in bed, cutting food, salivation, swallowing,
and breathing. &nbsp;A single point change on the ALSFRS-R has a significant impact on ALS patients, such as the transition from independent
feeding to requiring assistance or independent breathing to needing to use a machine ventilator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PARADIGM</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PARADIGM is a prospective, multinational, randomized,&nbsp;double-blind,
placebo-controlled Phase 2b (NCT05357950) clinical trial of PrimeC in ALS. The trial included 68 participants living with ALS in Canada,
Italy, and Israel. 96% of the trial participants who completed the 6-month double-blind portion of the trial chose to receive treatment
with PrimeC through a 12-month open label extension. Furthermore, to date (June 2024) all participants that completed the 18-month trial
treatment duration, requested to continue PrimeC, which is provided to them in an Investigator Initiated Trial, not limited with time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously reported, in the 6-month double-blind segment of the
trial, the data showed clinically meaningful signs of efficacy with a 29% difference in favor of PrimeC vs placebo in analysis of the
intent to treat (ITT) population. In the PP top-line analysis&nbsp;from PARADIGM, a statistically significant slowing of disease progression
was observed with a 37.4% (p=0.03) difference in ALSFRS-R in favor of PrimeC vs placebo. Most patients enrolled in both the active and
placebo arms of the trial were concurrently treated with Riluzole, the ALS standard of care medication, indicating PrimeC slowed disease
progression well beyond the level afforded by the FDA approved ALS drug.&nbsp; &nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PrimeC</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PrimeC, NeuroSense&rsquo;s lead drug candidate, is a novel extended-release
oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed
to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation
and impaired ribonucleic acid (&ldquo;RNA&rdquo;) regulation to potentially inhibit the progression of&nbsp;ALS. NeuroSense completed a
Phase 2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically
significant changes in ALS-related biological markers indicating PrimeC&rsquo;s biological activity. PrimeC was granted Orphan Drug Designation
by the U.S. Food and Drug Administration and the European Medicines Agency.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About&nbsp;NeuroSense</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company
focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes
that these diseases, which include amyotrophic lateral sclerosis&nbsp;(ALS), Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease, among others,
represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients
to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers,
NeuroSense&rsquo;s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For additional information, we invite you to visit our&nbsp;website&nbsp;and
follow us on&nbsp;LinkedIn,&nbsp;YouTube&nbsp;and&nbsp;X. Information that may be important to investors may be routinely posted on our
website and these social media channels.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &ldquo;forward-looking statements&rdquo;
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo; &ldquo;will&rdquo; &ldquo;would,&rdquo; or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense Therapeutics&rsquo; current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to
predict and include statements regarding PrimeC as a potential treatment for people with ALS. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual
results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include
the risk that regulatory approvals for PrimeC will not be obtained in Canada or elsewhere; unexpected R&amp;D costs or operating expenses,
insufficient capital to complete development of PrimeC, a delay in the reporting of additional results from PARADIGM clinical trial, the
timing of expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best
path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely
and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and
future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the
ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense&rsquo;s filings with the Securities
and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about
the risks and uncertainties affecting NeuroSense is contained under the heading &ldquo;Risk Factors&rdquo; in the Annual Report on Form
20-F filed with the Securities and Exchange Commission on April 4, 2024 and NeuroSense&rsquo;s subsequent filings with the SEC. Forward-looking
statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except
as required under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Logo:&nbsp;https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information: Email:&nbsp;info@neurosense-tx.com, Tel: +972
(0)9 799 6183</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !8 4H# 2(  A$! Q$!_\0
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M;Q>;.HK],MZIU; YZC SCN1SU([5\=?\% RI_8U_:!8\Y^'NL\ G# 1 E2<
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M&US=.[13/JBSPR:MX/MI)]ELHNCK>F0!+V[O=:L+*U^UO^B'[87[2EE^SO\
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M+<5AZ]=U<'[:+;INK0KXG#JM"M"$Y4TOY8O^"=7Q)\7_ !._;D^".I>-[_\
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M[MHI!/#HNFS7MUJ&IPZ4DT4,]Z;[5;_4=9N8;:;5+V>&RTRST[TJ;E.=*5;
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MTD]>GP?"]KFLZX7"JHX[\#/7U!QGDC(R.#QFJ[!0"."<_*"=H4$CY 8]A"C
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MFMV\,37WA[Q%90RM]DU735GA5X'EDBO+.:QU:QN+G3KRQNI_A/\ :I_X))?
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MEA),LD9D26,.J;)"BI&YDD4#]H 5W!L98LZKEFW .RMM9&^=6VJCE!$-@<
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MP^U?6M#U&[UC0].O=(M[/2+EX_)LX3<Z3;6]E<65E:+;QM:6MK<W'TW\4_\
M@GS/XA_:/U+]J/X'_M%_$O\ 9P^)GC'1-/\ #GQ//A+0_"'C'0?'FEZ9;V-C
M:/-H?C;3]2T[2]273M.L;>2Z^S:C:-=:=I^L)IT>L+J%]J>G^SC^P);_ +,_
MQR^)GQ=\*?M!?&'Q!X?^*%U!K/BCX:^*I?#6LV/B7Q=_9*:?=^,?&WC#4=&O
M?%GB#6Y+^75-;M/['O?"=G:W>IM93VU_H]CIVGVVCG3]G92UMVEH_NM;T[NY
MS.EB5B.?V;=)OWGS1UC?73FO?R/M3Q[X2\*^-_"6N^&_&6A:)XF\.:A83C4-
M'\1Z7IVLZ1<)#&9XWNM/U:VO=/N/LTT4=S#]IM)DAN(8IU0O$A'XY_\ !&SX
M*_"77/V'[;5=<^''@OQ#JOC7QE\4-(\6ZCXA\.Z=K5YXFT+1_%&I>']$TC6)
MM7MKVXN-$LM'MAIUII:%]&CC6[E-N]]=W-Q-^U&OS>1HFK7#2M$MO87LK2H=
MCQ)#;RR.ZOAMI55W!RKA<;FCD ,;?SU?\$K?@3\>OB)^QUHFJ?#G]L;X@_!G
MP5XG\:_$ZQU#P3H7PS^$WBV31I;7Q-?:==:EX+\8>(O#]WJ_AO4-8M8%OKJY
M>;6H++6;B:]L8;6^E00&']VA--V?M.9==$Y.^GJO,K$QA+$4XJFW)TVD[Z)V
M5MSW'_@DUHO_  K;XV_\%%?@AX-N;J;X)?#+]H73K;X>VDD\MWIVBZIJ:>*;
M?Q-HUG>,&C>]L;72O#VG:E:"25E&G65[<&"^N;N)NA_X+<>,=>T3]F;X8^$[
M*YMK+PE\3/VA?AYX.^(]UJ$M_!H=YX.BM]<UR\T/Q'/IL4UW!X9U74M)L5\2
M&**Y9]%L[^V-G>"Z,-?H]^SI^S5\,/V7?AY#\./A?9:BNG2:IJ7B'7_$'B&_
M;6O&'C+Q5K31/K/BKQ=K\D<,NKZ[J1@MDGN##!;Q6]I96MK:V]O:0QKH?M _
ML]_#3]IKX6>(_A!\6-*GU?PCXC6UF/V.Z?3]5T75]-N#>:1XAT'4(E<V&M:5
M>;;FWG>&XM9]IM;^SO-/GN[.XE5(NJI->[=7?E?5V6M_EWL:+#U%@YTM>=\U
MHI[[V2=[)N_<_-C]HC]EW]MW]I3X<>#?A[=/^QE\/;3X?^._AYX_^'?BGP+=
M_&)M3\$WG@.]M[C0QX2M9_#D>GV=I-IEN^E&#3FMK)].G^RFW9%8I^P$:R&)
M//.Z0PE955>)91AI0B2*4<%BQMHY DD8#)(BEI1%^8'P]_X)G^)_#UGHG@'X
MC?MJ?M$?%O\ 9^\--8PZ7\#-8/AKP]I.IZ)H]S;7&C>$O&7C+0[1/&'B3P=9
MK:6MK<>&;>_T72]2L;2VTZ]AETU);.;]3S""<DC=N!! *@ 'H0K -Q\PW;L2
M8<#Y45%7E%W5.2EH]DX^F_?K_D/"4.2+]K3E&5MG-23^Y_TC\9/VGO"/A30O
M^"JG_!/#Q'I'AK1-(U7QA8?M$R>)]9TK3=/L+WQ+J.G?#]AHTNOWT$$-SKE]
M#:7,J6,^J2W?V6"*:*VGL7$"R/\ V_?"?A+3?VU_^"8GC'3- T'3_$WB/]I'
MQ!9:_P")++1+.UUKQ#:V?@S1%TFUUG6;.T^UZO'8/%;IIJZE/<V]G$7-HT<L
M09?M7]K?]C/PC^U;8> -2G\:>,/A5\4_A%XAD\5?"CXM^ ;BVMO%'@_5KI+9
M-2@:*9%@U71=7%G9R:CIK2V<S3VEM-:7]F\;;_D_QM_P2M\1?$_7/A1X\^)7
M[;'Q^\5?%OX6^*KCQ)IOQ/\ [(\#:9J>G6Z6]M_96D>!/#%MI4G@GP*+'4[?
M^VKW55\/:_JNN7CK;:C<-I=I8:?:Z0G3T<IV:I35K2?O--15TN[6^B.>M0JN
MIB73P\FJE?#3C+GBKQIRCSRLY7T2;L]7T/UM^3Y5SM158*2H4*L9A=& D#^;
ML5<^:@95.=Q1AE?QZ>VL3_P6K@LOLEC$B_L(3&.W:"V$,EP?B;$XDCL]XDCD
MB-T89D4Q*([J'[0K37%E=#]>-$TF;2-'TO2I]8U+6I]-TRRTZ76M5%B=6U::
MUMH89]7U5K&RL;!]5U*>-[Z^>RL+&Q>ZF?R;"&(+$/B']I?]AB'XX?%GP%^T
M'\./C9X^_9V^/'@'0[GPC:>/_ VFZ!KMMKO@R\NKN^G\->)?#/B&WDT_5[2.
M]O[ZYM&N9FC5[R47MMJ MM*.FYT91@ZO,[*<91B[-ZM63T.K$TIU(46H<\J<
MH2<+I7Y7=J[=M=MS[DA6"!5BMX(X+9(S%L2-$PI8%(S$(RPC7S99"S^6J+-N
M*R>8[I^.'_!5'P;X4C^(G[ /CB+P]H<'BV[_ &W/@YX<OO$\6CZ<FNZAHS?:
M[N'2K_5VMCJ&H:7#/:0RVUI-+>6=O="&6")+M(Y%_4GX-_#'4?A5X(L_"VM?
M$KQ[\6==:\OM6U[QW\1M1M-1U_6]8U*=;FYEBM;"SL-&T#2+1U6WT3P]H=A9
MZ7I%A%#;11S2H]S+\J_M:?L/>)?VJO&GP\\27/[2/C7X;Z'\*?%'AWX@> _"
M7AKP'\/M5M]'^(OAU[G[/XLN-9U[3+K5=5\Z"X:!]#U&2?157?NM9!*R I2C
M3D[RNG=7LWO=7[Z7#$1G4IQY*#C-6:7-%)->=[/;7\#[W=@(VW8899@&5F)&
MU1Y:A<Y:5FVJI^9B^U8W&!7XJ?LGZM9?%7_@J5^WQXG^)9@U'QW\&]+\&_#C
MX,V6KQPR7/A'X:K_ &B/$=]X-34#YVF+K5ZNBW^LZGI@2-[KQ'.;FX6WU(6@
M_8OPAH6NZ%X6T#1_$WBNY\:^(M,TJTL]9\77>D:3H-QXCU&&)([G5IM%T."V
MTC2VO&0R&PTN&"R@WLL**=K#X3_:,_X)V>&OC%\8M._:/^%?QB^(_P"S-^T%
M:Z;:Z)JGQ&^&)T^[C\6:-911VMM:>+/#NL V6LRI8P6EA-))<1VFJ6>G:1!K
MMAJZ:'HJZ>4G!3J<TG%332E9NSZ:+6WR%7HU)0H.*<I4YQE.FFE=)W<;MVUV
MW/JOP%\!/@S\+_''Q'^)7P]^'WA[PGXR^+6H:=J/Q%UO0K.:UN?$^HZ:]]+:
MWE_:I)+;6MTLVJZA>WYL;/3AJ>I:C>:CJPO-0G-RORC_ ,%)?V;?&/[3?P;\
M&>&?AGXU\,^%/B9X%^*_ACXH_#[1?&-U]G\+>/O$O@RUUVZ3PCJ$(29;B>;S
M_P"V;$3VVJV<-UI"?VA86MDUQJUC[7^SM^RW)\$]3\1>-_&WQB^)/[0'Q?\
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
